Inclusion Criteria

Inclusion criteria:

1. Cytologically or histologically confirmed stages II or III non-squamous NSCLC

2. No evidence of tumour invading major blood vessels and no active hemoptysis (bright
red blood of at least ½ teaspoon) in the 28 days prior to randomization.

3. No prior systemic therapy for NSCLC. Prior surgery and/or extra-thoracic irradiation
is permitted.

4. Presence of at least one measurable target lesion

5. Age 18 or greater.

6. WHO performance status of 0 or 1.

7. Acceptable pulmonary function as defined by a Fev1 of ≥30% and a DLCO of ≥40% of
predicted

8. Life expectancy of at least 12 weeks.

9. Adequate hematological, renal and hepatic functions

- Absolute neutrophil count >2x109/l.

- Platelet count > 100x109/l.

- Total bilirubin < 1.5 x UNL

- ASAT/ALAT < 2 x UNL

- Alkaline phosphatase < 5 x UNL

- Creatinine < 130 μmol/L

- Creatinine clearance > 60 ml/min; measured or calculated

10. Urine dipstick for proteinuria < 1+. If urine dipstick is ≥ 1, 24 hour urine must
demonstrate < 500 mg of protein in 24 hours.

11. No pre-existing sensory neurotoxicity grade 2 (CTC)

12. No active (uncontrolled) infection requiring antibiotics

Exclusion criteria:

1. Mixed tumor types with small cell lung cancer or squamous cell carcinoma

2. Other serious diseases, such as heart failure, angina pectoris, myocardial infarction
within the last 6 months, uncontrolled hypertension

3. Serious non-healing wound or ulcer.

4. ASAT and ALAT > 1,5 x UNL

5. alkaline phosphatase 5 x UNL

6. Evidence of bleeding diathesis or coagulopathy.

7. Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule; those conditions
should be assessed with the patient before registration in the trial.

8. Participation in other trial with investigational drug or treatment modality.